Related Experiment Video

Updated: Oct 19, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Genomic organization of human JAK2 and mutation analysis of its JH2-domain in leukemia

J Cools1, P Peeters, T Voet

  • 1Center for Human Genetics and Flanders Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium.

Cytogenetics and Cell Genetics
|August 18, 1999
PubMed

Insights

Activating mutations in the Janus kinase 2 (JAK2) gene are rare in human leukemia. Researchers analyzed JAK2's genomic organization and found no activating mutations in the kinase-like JH2 domain in leukemia samples.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • The Janus kinase (JAK) family, including JAK1, JAK2, JAK3, and TYK2, is crucial for cytokine receptor signaling to the nucleus.
  • ETV6-JAK2 fusion genes have been implicated in lymphoid and myeloid leukemias.
  • Mutations in Drosophila JAK homologues (hopscotch) can cause leukemia-like defects, with one affecting the JH2 domain leading to constitutive kinase activation.

Purpose of the Study:

  • To investigate the role of human JAK2 in leukemogenesis.
  • To determine the genomic organization of human JAK2.
  • To analyze for activating mutations in the JAK2 JH2 domain in leukemia samples.

Main Methods:

  • Cloning and genomic organization determination of human JAK2.
  • Mutation analysis of exons 13-19, encoding the kinase-like JH2 domain.
  • Analysis of leukemia samples.

Main Results:

  • Human JAK2 consists of 24 exons spanning approximately 150 kb.
  • No activating mutations were detected in exons 13-19 of JAK2 in the analyzed leukemia samples.
  • The study suggests activating mutations in the JAK2 JH2 domain are infrequent in human leukemia.

Conclusions:

  • The genomic organization of human JAK2 has been elucidated.
  • Activating mutations within the JAK2 JH2 domain appear to be a rare event in human leukemogenesis.
  • Further research may be needed to explore other potential roles of JAK2 in leukemia development.

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...